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Open access under tBoron Neutron Capture Therapy (BNCT) involves the selective accumulation of boron carriers in tumor
tissue followed by irradiation with a thermal or epithermal neutron beam. This therapy is therefore a cel-
lular irradiation suited to treat tumors that have inﬁltrated into healthy tissues. BNCT has been used clin-
ically to treat patients with cutaneous melanomas which have a high mortality. Human normal
melanocytes and melanoma cells were treated with BNCT at different boronophenylalanine concentra-
tions for signaling pathways analysis. BNCT induced few morphological alterations in normal melano-
cytes, with a negligible increase in free radical production. Melanoma cells treated with BNCT showed
signiﬁcant extracellular matrix (ECM) changes and a signiﬁcant cyclin D1 decrease, suggesting cell death
by necrosis and apoptosis and cell cycle arrest, respectively. BNCT also induced a signiﬁcant increase in
cleaved caspase-3 and a decrease in the mitochondrial electrical potential with selectivity for melanoma
cells. Normal melanocytes had no signiﬁcant differences due to BNCT treatment, conﬁrming the data
from the literature regarding the selectivity of BNCT. The results from this study suggest that some sig-
naling pathways are involved in human melanoma treatment by BNCT, such as cell cycle arrest, ECM
changes and intrinsic apoptosis.
 2013 Elsevier Ltd. Open access under the Elsevier OA license. Signiﬁcance
Metastatic melanoma remains a highly lethal disease, with an
incidence that continues to increase faster than any other cancer
and almost adjuvant treatments fail to control this malignancy.
Boron Neutron Capture Therapy was used is this work with selec-
tive treatment for melanoma cells with minimum effects in normal
cells. This therapy induces cell death by apoptosis and cell cycle ar-
rest only in melanoma cells.1. Introduction
Boron Neutron Capture Therapy (BNCT) is a binary treatment
modality that involves the selective accumulation of boron carriersiochemistry and Biophysics,
lo, 05503-900 SP, Brazil. Tel.:
aião-Flores), durvanei@usp.br
he Elsevier OA license. in a tumor, followedby irradiationwitha thermalor epithermalneu-
tron beam (Monti Hughes et al., 2011). The neutron capture reaction
withaboron-10 (10B)nucleusyieldshigh linearenergy transfer (LET)
particles, alpha and 7Li, with a range of 5–9 lm, thus BNCT is a puta-
tive cell-selective radiation therapy with the potential to control lo-
cal recurrences of malignant tumors (Nakamura et al., 2011). These
particles can only travel very short distances and, as such, release
their damaging energy directly to the tissue that contains the boron
compound. Cell death is triggered by the release of these charged
particles, which create ionisation tracks along their trajectories,
thereby resulting in cellular damage (Toppino et al., 2013).
BNCT has two advantages. Firstly, the dose of radiation given in
the neutron beam can be quite low; secondly, the local decay and
action allow the surrounding healthy tissue to be spared damage
due to radiation (Barth et al., 2005).
BNCT has been used clinically to treat patients with cutaneous
melanomas (Mishima, 1996). These patients were either not candi-
dates for, or had declined, conventional therapy (Barth et al., 2004).
Melanoma is the most aggressive skin cancer and frequently in-
volves distant and locoregional spread, usually with no efﬁcient
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highly lethal disease, with an incidence that continues to increase
faster than any other cancer (González et al., 2004). Almost all
adjuvant treatments fail to control this malignancy (Pawlik and
Sondak, 2003).
BNCT has a strong local radiotherapy effect. The efﬁcacy of the
method in cancer therapy requires sufﬁcient accumulation of
boron into the tumor and an irradiation in tumor location (Joensuu
et al., 2011). Only cells that have 10-boron are damaged by thermal
neutrons. So, this therapy is a cellular radiation suited to treat local
tumors or those inﬁltrate near healthy tissues (Esposito et al.,
2008).
BNCT could be an attractive tool to improve response over the
standard radiotherapy treatment delivering high dose to tumor
while reducing normal tissue effect, due to the different boron up-
take in normal and tumor cells (Menéndez et al., 2009).
There are no published results about the BNCT effect on normal
melanocytes compared to melanoma cells, and these data are ex-
tremely important to know the effectiveness of BNCT versus the
side effects incidence in healthy tissues. There is also no data about
signaling pathways involved in the melanoma treatment. The aim
of this study was to evaluate the selectivity and signaling pathways
involved in melanocytes and melanoma treatment with BNCT.2. Materials and methods
2.1. Cell lines
A human melanoma tumor cell line (SK-MEL-28) was cultivated
in 75 cm2 ﬂasks with RPMI-1640 (Cultilab) medium supplemented
with 10% inactivated fetal bovine serum (Cultilab), 2 mM
L-glutamine (Sigma Chemical Company) and 0.1 g/mL streptomy-
cin (FontouraWyeth AS). A human primary culture of melanocytes
isolated from foreskin was cultivated with 254CF medium
(Life Sciences), supplemented with 10% HMGS growth factors
(Life Sciences) and 0.1 mg/mL streptomycin (FontouraWyeth AS)
as previously described (Fernandez et al., 2005).
Adherent cell suspensions were propagated by treatment of the
culture ﬂasks with 0.2% trypsin and then inactivated in 10% fetal
bovine serum (FBS)-enriched medium. The nonadherent cells were
centrifuged twice, resuspended in medium and then seeded in
plates and allowed to grow for 24 h.
2.2. Boronophenylalanine (BPA)
10B-enriched (>99%) BPA was purchased from KatChem and
converted to a fructose 1:1 complex to increase its solubility (Cod-
erre et al., 1994).
2.3. Cells treatment and BNCT irradiation for MTT and lipid
peroxidation tests
Melanocytes were seeded in 96-well plates at concentration of
105 cells/mL and allowed to grow for 24 h. They were then treated
with different concentrations of BPA, from 40 to 0.52 mg/mL,
which corresponds to 2100–27.5 lg 10B/mL for MTT assay and
from 8.32 to 0.52 mg/mL, which corresponds to 440–27.5 lg 10
B/mL for lipid peroxidation test. After incubation with BPA for
90 min, the cells were irradiated at the BNCT research facility at
the Nuclear and Energetic Research Institute (IPEN, Brazil) Coelho
et al., 2002 for 120 min using the IEA-R1 nuclear reactor operating
at a power of 3.5 MW. The thermal neutron ﬂux, epithermal
neutron ﬂux and fast neutron ﬂux at the irradiation position were
(2.31 ± 0.03)  108, (4.60 ± 0.10)  106 and (3.50 ± 0.10)  107
n/cm2 s, respectively. The gamma dose rate in air at the irradiationsite was 3.50 ± 0.80 Gyh1. Before irradiation, the BPA-enriched
incubation medium was removed and the cells were washed in
0.9% saline solution. Another cell group was irradiated without
BPA (beam only) and was designated as the ‘‘irradiated control’’.
A non-irradiated and BPA-free group was also studied and was
designated as the ‘‘control’’. Images of the control and treated cells
were recorded by a camera (Sony Cyber-shot 7.2 mega pixels)
coupled to an optic inverted microscope (Carl Zeiss), magniﬁed
by 40.
2.4. Cells treatment and BNCT irradiation for soluble collagen
quantiﬁcation and ﬂow cytometry tests
Melanocytes and SK-MEL-28 melanoma cells were seeded in
24-well plates at a concentration of 105 cells/mL and allowed to
grow for 24 h. SK-MEL-28 melanoma cells were treated with
3.7 mg/mL BPA in all ﬂow cytometry tests (this value is equivalent
to 192.0 lg 10B/mL),which corresponds to the inhibitory concentra-
tion of 50% (IC50) for this compound in this cell line (Faião-Flores
et al., 2011a). Melanocytes were treated with 34.4 mg/mL BPA in
all ﬂow cytometry tests (this value is equivalent to 1.8 mg 10B/mL),
which corresponds to the IC50 for this compound in this cell line.
After 90 min of incubation with BPA, the cells were irradiated at
the BNCT research facility at the Nuclear and Energetic Research
Institute (IPEN, Brazil) Coelho et al., 2002 for 30 min, using the
IEA-R1 nuclear reactor operating at a power of 3.5 MW. The analysis
was performed 6 h after BNCT treatment. The thermal neutron ﬂux,
epithermal neutron ﬂux and fast neutron ﬂux at the irradiation
position were (2.31 ± 0.03)  108, (4.60 ± 0.10)  106 and
(3.50 ± 0.10)  107 n/cm2 s, respectively. The gamma dose rate in
air at the irradiation site was 3.50 ± 0.80 Gy h1. Before irradiation,
the BPA-enriched incubation medium was removed and the cells
were washed in 0.9% saline solution. Another cell group was irradi-
atedwithout BPA (beamonly) andwas designated as the ‘‘irradiated
control’’. A non-irradiated and without BPA group was also studied
and was designated as the ‘‘control’’.
2.5. Cellular viability assay – MTT
The cellular viability of the melanocytes was determined using
a colorimetric methodology known as MTT (3-(4,5-dimethylthia-
zol-2-y1)2,5-diphenyl tetrazolium bromide) (Sigma) Mosmann,
1983. MTT is reduced in metabolically active cells to form insoluble
purple formazan crystals, which are solubilized by the addition of a
detergent. The color is then quantiﬁed by spectrophotometry. After
irradiation, the culture medium was removed for lipid peroxida-
tion (LPO) analysis and 10 lL MTT reagent (5 mg/mL) (Sigma–Al-
drich Corp.) was added to each well. The plates were incubated
at 37 C for 3 h, protected from light. Blue formazan crystals thus
formed were pelleted to the bottom of the well by centrifugation,
separated from the supernatant and dissolved in 150 ll of
dimethylsulfoxymide. The optical density at 540 nm was deter-
mined by absorbance spectrometry using a microplate reader. A
linear relationship between cell number and absorbance was
established, enabling an accurate, straightforward quantiﬁcation
of changes in proliferation. The mean values of several experiments
were presented in a linear regression model, and the IC50 was
calculated.
2.6. Lipid peroxidation (LPO)
The oxidative stress on unsaturated lipids in cell membranes
was evaluated by determining the amount of malondialdehyde
(MDA), which is the ﬁnal product of fatty-acid peroxidation that
reacts with thiobarbituric acid (TBA) to form a colored complex.
Thiobarbituric acid reactive substances (TBARS) were quantiﬁed
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1979. The supernatant of the samples obtained after irradiation
and before carrying out the MTT method was used for LPO. This
experiment was performed 6 h after thermal neutron irradiation.
2.7. Soluble collagen quantiﬁcation by Sirus Red assay
The Sirus Red cytochemical staining test evaluates the quantity
of collagen in a sample (Koren et al., 2001). The dyes used for the
Sirus Red test react speciﬁcally with basic groups in the collagen
molecule (Junqueira et al., 1979; Pickring and Boughner, 1991).
After irradiation, plates with the supernatant (metabolized cul-
ture medium) of melanoma cells and melanocytes were placed in
an incubator at 37 C overnight without lids to dry the contents.
Then, saturated Bouin solution (Koren et al., 2001) was added in
each well, and the samples were incubated for 1 h at the room
temperature. The dye was removed and 300 lL distilled water
was added. The plate was dried at room temperature for approxi-
mately 2 h. After this period, 200 lL 0.1% picrosirius dye was added
for 1 h, protected from light. The dye was removed and 250 lL
0.01 M HCl was added. After that, the HCl solution was removed,
and the samples were incubated with 150 lL 0.1 M NaOH for
30 min. The optical density of the samples was read at 550 nm in
a spectrophotometer. This experiment was performed 6 h after
thermal neutron irradiation.
2.8. Assessment of mitochondrial membrane potential by ﬂow
cytometry
Rhodamine 123 is a cationic lipophilic ﬂuorescent chemical that
accumulates speciﬁcally in mitochondria of living cells (Kennady
et al., 2004). Thus, this agent binds only inmetabolically activemito-
chondria, resulting in a ﬂuorescent emission. After irradiation, the
culture medium was removed and adherent cells were trypsinized.
Melanoma cells andmelanocytes were pelleted by centrifugation at
1800 rpm for 10 min and resuspended in 5 lL Rhodamine 123
(5 mg/mL) for 30 min at 37 C. The cells were then washed with
phosphate-buffered saline (PBS) and resuspended in FACS ﬂow buf-
fer (Becton Dickinson). The samples were analyzed for ﬂuorescence
(FL-1H detector) on a Becton Dickinson FACScan ﬂow cytometer
using Cell Quest software. This experiment was performed 6 h after
thermal neutron irradiation.
2.9. Cyclin D1 quantiﬁcation by ﬂow cytometry
The type D cyclins (with their partner CDKs) form a regulatory
unit of the G1/S transition that is frequently impaired in neoplásicas
(Li et al., 2006). After irradiation, the culture medium was removed
and adherent cells were trypsinized. Melanoma cells and melano-
cytes were pelleted by centrifugation at 1800 rpm for 10 min and
incubated with 1 lg speciﬁc Anti-cyclin D1 antibody (Santa Cruz,
USA) and 10 lL Triton X-100 (0.1%) for 1 h at 4 C. The cells were
then resuspended in FACS Flow buffer. The samples were analyzed
for ﬂuorescence (FL-1H detector) on a Becton Dickinson FACScan
ﬂow cytometer using Cell Quest software. This experimentwas per-
formed 6 h after thermal neutron irradiation.
2.10. Annexin-V assay
Annexin V is a small Ca2+-dependent protein with high afﬁnity
for phosphatidylserine (PS) Vermes et al., 1995. In normal living
cells, PS is located in the inner layer of the cell membrane only,
but in apoptotic cells this phospholipid is translocated to the outer
leaﬂet. PS exposure on the surface of cells functions as tags for spe-
ciﬁc recognition for phagocytosis by macrophages or neighboring
cells (Fadok et al., 1992). Annexin V was used to detect apoptosisat an early stage in the cells together with propidium iodide, which
binds to DNA in cells that have lost membrane integrity (necrotic
or late apoptotic cells).
After treatment, the cells in the supernatant and the adherent
cells were washed with PBS and binding buffer (10 mM HEPES
pH7.5 containing 140 mMNaCl and 2.5 mMCaCl2) and stainedwith
1 lg annexin V-FITC (Santa Cruz Biotechnology, USA) and 18 lg/mL
of propidium iodide (PI) (Sigma–Aldrich Corp.). Each sample was
analyzed by ﬂow cytometry using the FL-1 and FL-2 channels to dis-
tinguish the apoptotic, necrotic, and viable cell populations. The
analysis was performed on a FACSCalibur ﬂow cytometer using
the Cell Quest software (FACSCalibur; Becton Dickinson). The cas-
pase-3 inhibitor zDEVD-fmk (Becton Dickinson, USA) was prepared
as stock solution in 100% DMSO (100 mM). Final concentration in
serum-free medium was 1 mM for zDEVD-fmk. Cells were incu-
bated with caspase inhibitor 1 h before addition of BPA. Control
wells were incubated with corresponding DMSO concentration.2.11. Cleaved caspase-3 activity by ﬂow cytometry
Caspases represent a family of cysteine proteases that are com-
mon downstream effectors of apoptosis (Chen et al., 2001). After
irradiation, the culture medium was removed and adherent cells
were trypsinized. Melanoma cells and melanocytes were pelleted
by centrifugation at 1800 rpm for 10 min and incubated with
1 lg of speciﬁc Anti-caspase 3 PE antibody (Santa Cruz, USA) and
10 lL of Triton X-100 (0.1%) for 1 h at 4 C. The cells were then
resuspended in FACS Flow buffer. The samples were analyzed for
ﬂuorescence (FL-1H detector) on a Becton Dickinson FACScan ﬂow
cytometer using Cell Quest software. This experiment was per-
formed 6 h after thermal neutron irradiation.
The caspase-3 inhibitor zDEVD-fmk (BectonDickinson, USA)was
prepared as stock solution in 100% DMSO (100 mM). Final concen-
tration in serum-freemediumwas 1 mM for zDEVD-fmk. Cells were
incubated with caspase inhibitor 1 h before addition of BPA. Control
wells were incubated with corresponding DMSO concentration.2.12. Statistical analysis
The values are expressed as the mean ± standard deviation
(s.d.). The data were analyzed using one-way analysis of variance
(ANOVA), and signiﬁcant mean differences were determined using
multiple comparisons by the Tukey–Kramer test at the p < 0.05
level. Signiﬁcant differences between the control and treated
groups are indicated by p < 0.001, p < 0.01, and p < 0.05.3. Results
3.1. BNCT induced both low levels of cell death and free radical
production in normal melanocytes
Melanocytes treated with BNCT showed low levels of cell death.
The IC50 value was 34.4 mg/mL, which corresponds to 1.8 mg/mL
10B (Fig. 1). The cellular viability (IC50 value) of the irradiated
control did not show any signiﬁcant difference compared to the
control group.
After BNCT treatment, the melanocytes exhibited an increase in
free radical production, and this increase was greater only when
higher BPA concentrations were used (Fig. 2). However, the in-
crease in free radical production in the highest BPA concentration
used was approximately only 1.5 times higher than that of the con-
trol group. The lower BPA concentrations did not show signiﬁcant
differences. The irradiated control also did not exhibit any differ-
ences compared to the control group.
Fig. 1. Cellular viability of normal melanocytes after BNCT. The percentage of viable
cells was plotted against the different BPA concentrations followed by thermal
neutron irradiation. The linear regression curve and IC50 were calculated using
Graph Pad Prism Instat 3 software. The IC50 value estimated was 34.4 mg/mL
(approximately 1.8 mg 10B). Data were obtained from three independent experi-
ments and results were represented as mean ± s.d.
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analysis after BNCT treatment. None of the BPA concentrations in-
duced morphological changes. The presence of apoptotic bodies,
debris formation and cytoskeleton disarray was also not detected
(Fig. 3). Only the highest BPA concentration showed a slight de-
crease in conﬂuence, which is consistent with the free radical pro-
duction observed when using this concentration. The cells of the
irradiated control presented insigniﬁcant alterations and little cell
damage.3.2. Extracellular matrix changes in melanoma cells after BNCT
After BNCT, the extracellular matrix of normal melanocytes and
melanoma cells was analyzed by Sirus Red staining. The extracel-
lular matrix of melanoma cells treated with BNCT showed dra-Fig. 2. Malondialdehyde production in normal melanocytes after BNCT at different BPA
cells without treatment (control). Data were obtained from three independent experim
control. p < 0.05; p < 0.01 compared to control.matic changes, as evidenced by a decrease in soluble collagen
synthesis (Fig. 4). The decrease of soluble collagen synthesis in
melanoma cells treated with BNCT was approximately 2.7 times
higher than in the control group. Melanocytes did not present
any differences in soluble collagen synthesis after BNCT treatment.
Additionally, the irradiated group did not show signiﬁcant differ-
ences in comparison with the control group in these normal and
tumor cell lines.
3.3. The mitochondrial electric potential decreases after BNCT in
melanoma cells
BNCT induces a decrease of the mitochondrial electric potential,
thereby causing cell death in SK-MEL-28 melanoma cells. After
BNCT, the melanoma cells had their mitochondrial electric poten-
tial reduced by approximately 12.3 times compared to the control
group (Fig. 5). Melanocytes treated by BNCT did not show signiﬁ-
cant differences in this electric potential. These data conﬁrm the
cellular viability assay, which provided a high IC50 value for normal
melanocytes. The irradiated group also did not present differences
compared to the control group for either cell line.
3.4. BNCT induces cell death by necrosis and apoptosis in melanoma
cells
After BNCT treatment,melanocytes andmelanomacellswere ob-
served as to the ability in necrosis and apoptosis induction (Fig. 6A).
SKMEL-28 melanoma cells treated by BNCT showed approximately
50%of cell population innecrosis and in late apoptosis (Fig. 6B). After
zDEVD-fmk inhibitor addition, the necrosis population was in-
creased, whereas apoptosis population was decreased. Cells treated
with this inhibitor showed reduced capacity in apoptosis induction.
This is due to the ability of this caspase-3 inhibitor to provoke high
inﬂuence in the both apoptotic pathways.
Melanocytes did not present signiﬁcant differences in necrosis
or apoptosis in comparison to the control and irradiated control
groups (Fig. 6C).
3.5. Cell cycle progression decreases in melanoma cells after BNCT
The cyclin D1 marker was used to quantify cell cycle progres-
sion in the G1-S phases. BNCT was able to induce a decrease in cy-concentrations and after neutron irradiation alone (irradiated control) compared to
ents and results were represented as mean ± s.d. ns: not signiﬁcant compared to
Fig. 3. Morphological aspects of normal melanocytes after BNCT at all BPA concentrations compared to the control group and irradiated control. Magniﬁcation: 40.
Fig. 4. Soluble collagen synthesis in melanoma cells and melanocytes after BNCT
and neutron irradiation alone (irradiated control) compared to cells without any
treatment (control). Data were obtained from three independent experiments and
results were represented as mean ± s.d. ns: not signiﬁcant compared to control.
p < 0.05; p < 0.01; p < 0.001 compared to control.
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this progression decrease was not signiﬁcant (Fig. 7A). There were
no signiﬁcant changes in cyclin D1 expression in melanocytes. The
irradiated control did not present signiﬁcant alterations in this
marker in either cell line.
3.6. Apoptosis induction by cleaved caspase-3 in melanoma cells after
BNCT
Cleaved caspase-3 was used to verify the presence of cell death
by the apoptosis pathway. In melanoma cells, BNCT was able to in-
duce signiﬁcant caspase-3 cleavage, indicating apoptosis activation
(Fig. 7B). There was a small decrease of cleaved caspase-3 in mela-
nocytes after BNCT treatment. The irradiated control group did not
exhibit any signiﬁcant differences compared to the control group
for either cell line, thus conﬁrming all previous results shown in
this work.
To conﬁrm whether or not caspase-3 activation is involved in
the apoptosis of cells triggered by BNCT, it was used the caspase
inhibitor zDEVD-fmk before BNCT treatment. The results indicated
that BNCT induces caspase-3 activity increase and apoptosis with-
out the caspase inhibitor. After treatment with BNCT and thezDEVD-fmk, the inhibition of BNCT-mediated caspase-3 activation
was accompanied by the moderate necrosis expression increase.4. Discussion
Advancements in cancer therapy depend on the development of
new drugs, drug delivery systems and target therapies. A major
challenge in drug delivery is to increase the efﬁciency by which a
compound can deliver themaximumamount of a therapeutic agent
to the tumor while minimizing any adverse effects to normal cells
(Chakrabarti1 et al., 2012). To fully develop its treatment potential,
BNCT requires the combination of a suitable thermal neutron ﬂux
and a selective uptake of 10B in the target tissue. The latter condi-
tion is more critical because none of the boron carriers used for
experimental or clinical purposes so far have shown optimal selec-
tivity for cancer cells compared to normal cells (Menichetti et al.,
2009). The BNCT treatment induced moderate malondialdehyde
production only at the highest concentration of BPA inmelanocytes.
The other concentrations, along with the irradiated control, did not
manifest an appreciable increase of malondialdehyde, demonstrat-
ing that this therapy did not inﬂuence free radical production in
normal cells. In SKMEL-28, B16F10, IPC-298 and MEWOmelanoma
cells there were high malondialdehyde production (at least 10–30-
fold increase) after BNCT treatment in the same conditions (Faião-
Flores et al., 2011a).
It should be emphasized that the main criterion for the develop-
ment of successful boron-containing compounds in cells is a high
selectivity of these compounds for cancer cells over normal cells
(Gnewuch and Sosnovskym, 2002).
There is a decrease in normal melanocytes viability only in the
highest BPA concentrations followed by neutron irradiation. The
IC50 found here was signiﬁcantly high compared to SKMEL-28 mel-
anoma cells: IC50 = 34.4 mg/mL and 3.7 mg/mL in normal melano-
cytes and melanoma cells SKMEL-28, respectively. These results
conﬁrm the most selectivity of BPA for tumor cells in vitro without
inducing high cell death in normal cells, which has been reported
elsewhere (Faião-Flores et al., 2011a, 2012; Menichetti et al.,
2009). The increased BPA selectivity in vivo was studied in mice
bearing melanoma tumors consisting of B16F10 cells, and the
study found that the liver, heart and lungs do not take up boron
from BPA, whereas other organs, such as the spleen and brain, cap-
tured minimal quantities of this compound (Faião-Flores et al.,
2011).
Fig. 5. Representative overlaps of ﬂuorescence intensity and percentage values from melanoma cells and normal melanocytes marked with Rhodamine 123 analyzed by ﬂow
cytometry. The overlaps represent (A) control melanoma cells compared to irradiated group, (B) control melanoma cells compared to BNCT, (C) control melanocytes
compared to irradiated group and (D) control melanocytes compared to BNCT. (E) Percentage values of melanoma cells and normal melanocytes with active mitochondria
and/or viable cells are shown as the median ± s.d. Data were obtained from three independent experiments ns: not signiﬁcant compared to control. p < 0.05; p < 0.01;
p < 0.001 compared to control.
F. Faião-Flores et al. / Toxicology in Vitro 27 (2013) 1196–1204 1201Melanoma cells are strongly resistant to many chemotherapeu-
tic drugs, as demonstrated by their ability to block apoptosis and
stimulate tumor progression (Soengas and Lowe, 2003). The sur-
vival of adherent cells depends on an uninterrupted connection
with the components of the extracellular matrix (ECM), such as
laminin and ﬁbronectin (Makino et al., 2000). The interactions be-
tween cells and ECM are crucial for cell behavior, growth and death
(Wunrau et al., 2009). The detachment of adherent cells from the
ECM can induce apoptosis almost immediately, a process known
as Anoikis (Grossman et al., 2001). Despite melanoma being able
to produce low amounts of collagen, the tumor development andinvasion into adjacent tissue is often accompanied by increased
architectural disorder of the extracellular matrix (ECM) and cellu-
lar components especially at the invasive front of the neoplastic
mass (van Kempen et al., 2008). BNCT induced a decrease in colla-
gen synthesis in nearly 60% of melanoma cells without affecting
normal cells, involved with cell detachment of ECM, which fol-
lowed by apoptosis, could suggest cell death by Anoikis.
The observation of mitochondrial bioenergetics, among other
parameters, is important to establish the mechanisms by which
therapy may cause cell death (Wallace and Starkov, 2000). The
electronic gradient between the mitochondrial membranes during
Fig. 6. (A) Representative histograms of SKMEL-28 melanoma cells and melanocytes of control, irradiated control, BNCT and BNCT + zDEVD-fmk stained with annexin V
(FL-1H axis X), and propidium iodide (FL-2H axis Y) for cell quantiﬁcation. The distribution (mean ± s.d) is the number of viable, necrotic and apoptotic (B) melanoma cells and
(C) normal melanocytes. Data were obtained from three independent experiments ns: not signiﬁcant compared to control. p < 0.05; p < 0.001 compared to control.
1202 F. Faião-Flores et al. / Toxicology in Vitro 27 (2013) 1196–1204metabolism is known as mitochondrial electric potential (Dw)
Chen et al., 2009. The Dw is reduced when mitochondrial energy
metabolism is disrupted, notably during apoptosis (Fuller and Arri-
aga, 2003). We note that BNCT induced a decrease of mitochondrial
electric potential in melanoma cells by approximately 7 times
compared to the control group. This same result was not observedin normal melanocytes. The irradiated control did not present any
differences in either cell line.
The BNCT cytotoxic effect is mediated through many mecha-
nisms, which include interaction and damage of DNA followed by
activation of DNA damage-induced signaling pathways. These
pathways culminate in cell cycle arrest and/or apoptosis, necrosis,
Fig. 7. Expression of cell markers in melanoma cells and normal melanocytes
(median ± s.d.) by ﬂow cytometry. (A) Cyclin D1 expression after BNCT treatment
and neutron irradiation alone (irradiated control) compared to cells without any
treatment (control). (B) Cleaved caspase-3 expression after BNCT treatment and
neutron irradiation alone (irradiated control) compared to cells without any
treatment (control). The zDEVD-fmk inhibitor was used as caspase-3 inhibitor in
BNCT treated cells. Data were obtained from three independent experiments and
results were represented as mean ± s.d. ns: not signiﬁcant compared to control.
p < 0.05; p < 0.01; p < 0.001 compared to control.
F. Faião-Flores et al. / Toxicology in Vitro 27 (2013) 1196–1204 1203autophagy or mitotic catastrophe (Debatin and Krammer, 2004;
Okada and Mak, 2004). For this reason, some melanoma cells after
BNCT treatment presented substantial necrosis expression in-
crease, possibly by cellular communication between neighboring
cells and due to the limited BNCT efﬁcacy, which is almost exclu-
sively for cells carrying 10B irradiated by thermal neutrons. This
way, the apoptotic cascade signaling was interrupted.
The molecular mechanism of cyclin D1 induction during the cell
cycle is of central importance in understanding cell proliferation
control. Cyclin D1 is expressed at high levels in the middle and
at the end of the G1 phase of the cell cycle. High levels of cyclin
D1 in G1 promote entry into S phase and downregulation of this
marker indicates cell cycle progression arrest and in some cases
may result in cell death by apoptosis (Faião-Flores et al., 2011b;
Baker et al., 2005). BNCT caused a decrease in cyclin D1 expression
only in the melanoma cells and did not interfere with the G1 phase
of normal melanocytes. It known that BNCT can induce cell cycle
arrest at the G1 and G2 checkpoints in another cell lines as human
oral squamous cell carcinoma (Kamida et al., 2008). BNCT can in-
duce cell cycle arrest and apoptosis in both p53 wild-type or p53
mutant cells. However, p53 wild-type cells are more susceptive
to cell death than p53 mutant cells (Fujita et al., 2009). These data
can explain the cell death in SKMEL-28 melanoma cells that pos-
sess p53 wild-type. Thus, cell cycle arrest and associated cell death
would contribute to the decrease in cell viability caused by BNCT.
Moreover, BNCT was able to induce an increase in cleaved cas-
pase-3, another marker of cell death by apoptosis, in this tumor cell
line. This conﬁrms further results where BNCT also induced
apoptosis in a caspase 3-dependent manner, with PARP cleavagein tumor cells (Kamida et al., 2008). These results have also been
reported in murine melanoma cells (Sauter et al., 2002), and
now, in this study, they have also been conﬁrmed in human mela-
noma cells, showing that BNCT is effective against tumor cells.
5. Conclusions
BNCT can potentially target tumor tissue selectively, sparingnor-
mal cellsdamagedue to radiation. This therapydidnot induce signif-
icant changes in free radical production or in the morphological
characteristics of normal melanocytes. Furthermore, this therapy
decreased collagen synthesis, suggesting that ECM changes took
place in melanoma cells. Cyclin D1 and the mitochondrial electric
potentialwere signiﬁcantly reduced,whereascleavedcaspase-3 lev-
els increased only in the melanoma cells. These results suggest that
both the intrinsic apoptosis pathway and cell cycle arrest are in-
volved in this antitumor therapy. Thus, BNCT could be used to treat
many tumors, inducing cell death speciﬁcally in tumor tissueswhile
protecting healthy tissues.
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